Jyong Biotech Ltd. financials

MENS CIK 0001954488

Source: EDGAR filings · Built 2026-06-19T01:13:48Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2025FY 2025
EBITDA -2.51M -1.94M -2.67M
Working Capital -19.27M -11.92M
Net Debt 16.39M 77.00K
Return on Equity (ROE) 18.75% 8.27% 12.91%
Return on Assets (ROA) -22.48% -47.42%
Current Ratio 0.45× 0.02×
Debt-to-Equity -0.71× -0.00×
Cash Conversion Ratio 0.65× 1.20× 0.59×
Accruals Ratio -0.08× 0.10×

Income Statement

Concept FY 2025FY 2025FY 2025
Research and Development Expense 813.00K 927.00K 1.07M
Operating Expenses 2.61M 2.06M 2.80M
Operating Income (Loss) -2.61M -2.06M -2.80M
Net Income (Loss) Attributable to Parent -4.67M -3.02M -4.40M
Earnings Per Share, Basic $-0.06 $-0.04 $-0.06
Weighted Average Number of Shares Outstanding, Basic 73.01M 71.57M 71.57M
Earnings Per Share, Diluted $-0.06 $-0.04 $-0.06
Weighted Average Number of Shares Outstanding, Diluted 73.01M 71.57M 71.57M

Balance Sheet

Concept FY 2025FY 2025FY 2025
Assets, Current 15.54M 206.00K
Assets 20.78M 6.37M
Long-term Debt 2.12M
Liabilities, Current 34.81M 12.13M
Liabilities 45.68M 42.88M
Stockholders' Equity Attributable to Parent -24.91M -36.52M -34.07M
Common Stock, Shares, Outstanding 76.03M 73.36M

Cash Flow Statement

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MENS CIK 0001954488), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BXC

BlueLinx Holdings Inc.

KEY-PJ

KEYCORP /NEW/

SNX

TD SYNNEX CORPORATION